Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$124.33 - $156.75 $6.55 Million - $8.26 Million
-52,700 Closed
0 $0
Q2 2024

Aug 14, 2024

BUY
$113.33 - $163.85 $5.97 Million - $8.63 Million
52,700 New
52,700 $8.33 Million
Q4 2023

Oct 21, 2024

SELL
$67.31 - $124.76 $142,899 - $264,865
-2,123 Reduced 13.1%
14,077 $1.36 Million
Q4 2023

Feb 07, 2024

BUY
$67.31 - $124.76 $947,522 - $1.76 Million
14,077 New
14,077 $1.36 Million
Q2 2023

Oct 21, 2024

BUY
$106.4 - $157.19 $1.34 Million - $1.98 Million
12,587 Added 348.38%
16,200 $1.86 Million
Q2 2023

Aug 07, 2023

BUY
$106.4 - $157.19 $1.34 Million - $1.98 Million
12,587 Added 348.38%
16,200 $1.86 Million
Q1 2023

Oct 21, 2024

SELL
$117.53 - $155.99 $5.77 Million - $7.66 Million
-49,087 Reduced 93.14%
3,613 $497,000
Q1 2023

May 03, 2023

SELL
$117.53 - $155.99 $4.03 Million - $5.35 Million
-34,282 Reduced 90.47%
3,613 $497,000
Q4 2022

Feb 13, 2023

SELL
$100.86 - $132.13 $2.53 Million - $3.32 Million
-25,105 Reduced 39.85%
37,895 $4.91 Million
Q3 2022

Nov 07, 2022

BUY
$75.71 - $119.24 $53,224 - $83,825
703 Added 1.13%
63,000 $6.96 Million
Q2 2022

Aug 09, 2022

BUY
$62.69 - $88.44 $3.91 Million - $5.51 Million
62,297 New
62,297 $4.67 Million
Q1 2022

May 12, 2022

SELL
$63.15 - $90.42 $319,223 - $457,073
-5,055 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$77.28 - $99.42 $390,650 - $502,568
5,055 New
5,055 $455,000
Q2 2021

Aug 13, 2021

SELL
$69.38 - $86.75 $652,865 - $816,317
-9,410 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$72.25 - $168.95 $679,872 - $1.59 Million
9,410 New
9,410 $701,000
Q4 2020

Feb 12, 2021

SELL
$125.56 - $178.74 $446,993 - $636,314
-3,560 Closed
0 $0
Q3 2020

Nov 13, 2020

BUY
$127.12 - $172.34 $452,547 - $613,530
3,560 New
3,560 $500,000

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $10.7B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Jump Financial, LLC Portfolio

Follow Jump Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jump Financial, LLC with notifications on news.